TCMD Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Tactile Systems Technology Inc (TCMD). It details the overall technical consensus, moving average signals, momentum indicators like RSI and MACD, and key support and resistance levels. The analysis suggests a "Neutral" technical sentiment for TCMD, with indicators split between buy and sell signals.
TCMD SEC Filings - Tactile Systems 10-K, 10-Q, 8-K Forms
This page provides access to Tactile Systems (TCMD) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It features AI-powered summaries of these documents, highlighting key information for investors and traders. Recent filings detail stock transactions by executives, including sales to cover taxes and awards of performance stock units.
TCMD SEC Filings - Tactile Systems 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Tactile Systems (TCMD) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material events (8-K), and insider trading forms. It highlights recent filings such as a Form 144 for Kristie Burns to sell shares, detailed 2025 financial results showing revenue growth and profitability, and several amended Schedule 13G/A filings disclosing passive ownership stakes by Cadian Capital, Paradigm Capital, Morgan Stanley, and Dimensional Fund Advisors. The platform offers AI-powered summaries and real-time updates for investors and traders.
(TCMD) Volatility Zones as Tactical Triggers
This article from Stock Traders Daily analyzes Tactile Systems Technology Inc. (NASDAQ: TCMD), highlighting a weak near and mid-term sentiment but a strong long-term outlook. It identifies key support and resistance levels and outlines three distinct AI-generated trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, alongside a compelling 67.0:1 risk-reward setup.
Range Financial Group LLC Acquires Shares of 44,534 Tactile Systems Technology, Inc. $TCMD
Range Financial Group LLC has acquired 44,534 shares of Tactile Systems Technology ($TCMD) in the fourth quarter, valued at approximately $1.29 million, representing 0.20% of the company. While institutional ownership of TCMD stands at 83.43% with several firms increasing their stakes and analysts rating it a "Moderate Buy," company insiders have been selling shares, disposing of 55,276 shares in the past 90 days. Despite insider sales, analysts have set an average price target of $37.40 for the medical device company.
Vanguard (TCMD) reports 0 shares after internal realignment
Vanguard Group filed an amendment (Schedule 13G/A) stating it now has zero beneficial ownership of Tactile Systems Technology Inc. common stock. This change follows an internal realignment on January 12, 2026, where Vanguard's subsidiaries will report their holdings separately, as permitted by SEC Release No. 34-39538. Vanguard's previous beneficial ownership has been disaggregated, with no impact mentioned on the investment strategies.
[ARS] TACTILE SYSTEMS TECHNOLOGY INC SEC Filing
This article announces an ARS SEC filing by TACTILE SYSTEMS TECHNOLOGY INC (TCMD) on March 25, 2026. The filing has a low impact and neutral sentiment. It provides recent news and other SEC filings related to Tactile Medical.
3 Medical Device Companies Leveraging GenAI to Address Industry Challenges
This article examines the growing role of Generative AI (GenAI) in the medical instruments sector, highlighting its impact on diagnostics, patient monitoring, and clinical workflows. It reviews the industry's outlook, performance, key trends like GenAI transformation and M&A, and spotlights three companies—Globus Medical (GMED), Tactile Systems Technology (TCMD), and IRadimed Corp. (IRMD)—that are leveraging GenAI and strategic moves to address market demands. The article also provides financial metrics and projections for these companies, suggesting their potential as promising investments.
3 Medical Instrument Stocks Tapping GenAI to Navigate Industry Woes
The medical instruments industry is increasingly adopting generative AI (GenAI) to enhance diagnostics, patient monitoring, and intervention workflows, despite challenges like high implementation costs and macroeconomic pressures. This article highlights three companies—Globus Medical (GMED), Tactile Systems Technology (TCMD), and IRadimed Corp. (IRMD)—that are leveraging GenAI and other trends like M&A to navigate industry dynamics and show strong growth potential. The industry is characterized by its FDA-regulated nature and fragmentation, with a market valued at $39.34 billion in 2025 and projected to grow significantly.
CWA Asset Management Group LLC Buys Shares of 54,722 Tactile Systems Technology, Inc. $TCMD
CWA Asset Management Group LLC has purchased 54,722 shares of Tactile Systems Technology, Inc. (TCMD) for approximately $1.587 million, adding to significant institutional ownership. Despite this, company insiders, including CEO Sheri Dodd and VP Kristie Burns, have recently sold a substantial number of shares. Analysts maintain a "Moderate Buy" rating with an average target price of $37.40, following the company's recent beat on quarterly earnings and revenue estimates.
Price-Driven Insight from (TCMD) for Rule-Based Strategy
This article provides a price-driven insight for Tactile Systems Technology Inc. (NASDAQ: TCMD), highlighting a weak near and mid-term sentiment but a strong long-term outlook. It details specific institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and risk-reward ratios. The analysis emphasizes the exceptional 69.4:1 risk-reward setup targeting a 20.0% gain versus 0.3% risk.
Tactile Systems Technology, Inc. (NASDAQ:TCMD) Receives Consensus Rating of "Moderate Buy" from Analysts
Seven analysts have issued a "Moderate Buy" consensus rating for Tactile Systems Technology, Inc. (NASDAQ:TCMD), with an average one-year price target of $37.40. The company recently exceeded quarterly earnings expectations, reporting $0.46 EPS on $103.6 million in revenue, and analysts project $0.70 EPS for the current year. Despite recent insider selling activities totaling approximately $1.58 million, institutional investors hold a significant 83.4% stake in the medical device company.
Tactile Systems Technology, Inc. Common Stock TCMD ) Stock Price Today & Analysis
This article provides a detailed analysis of Tactile Systems Technology, Inc. (TCMD) stock, including its current price, fundamental financials, and corporate actions. It highlights the company's focus on medical devices for chronic diseases and answers frequently asked questions regarding buying TCMD stock on the Gotrade app, minimum investment, dividend policy, and market hours.
Andrea Pearson joins Tactile Medical (Nasdaq: TCMD) board and key committees
Tactile Medical (Nasdaq: TCMD) has appointed Andrea Pearson to its Board of Directors, effective March 9, 2026, expanding the board to nine members. She will also serve on the Compliance and Reimbursement Committee and the Nominating and Corporate Governance Committee. Ms. Pearson brings over 25 years of experience in scaling healthcare organizations, holding executive roles at companies like Harbor Health, DispatchHealth, and Healthgrades.
Tactile Systems (NASDAQ: TCMD) director receives 852-share RSU grant
Tactile Systems Technology Inc. director Andrea Pearson received a grant of 852 restricted stock units (RSUs) of common stock, as detailed in a Form 4 SEC filing. These RSUs were granted at no cash cost and will vest fully on the date of the company's 2026 annual meeting of stockholders. This transaction is categorized as routine equity compensation for a non-employee director and not an open-market purchase.
Tactile Systems (NASDAQ: TCMD) director Andrea Pearson files initial Form 3
Andrea Pearson, a director at Tactile Systems Technology Inc. (NASDAQ: TCMD), has filed an initial Form 3 with the SEC. This filing establishes her insider status, but reports no beneficial ownership of securities, nor any derivative holdings or transactions at this time. The Form 3 is a mandatory disclosure for new insiders and serves as a baseline for future reporting.
Tactile Medical Strengthens Board of Directors with Appointment of Andrea Pearson
Tactile Medical has appointed Andrea Pearson to its Board of Directors and to two committees, effective March 9, 2026. Pearson brings over 25 years of experience in scaling healthcare organizations, having previously held senior roles at Harbor Health, DispatchHealth, and HealthGrades. Her expertise in driving growth and understanding patient engagement in healthcare is expected to be invaluable to Tactile Medical.
Tactile Medical Appoints Andrea Pearson to Board, Strengthening Leadership in At-Home Healthcare Solutions 12
Tactile Medical (Nasdaq: TCMD) has appointed Andrea Pearson to its Board of Directors, effective March 9, 2026, where she will serve on the Compliance & Reimbursement and Nominating & Corporate Governance Committees. Pearson brings over 25 years of executive experience from the healthcare sector, with a strong background in driving growth and patient engagement at companies like Harbor Health, DispatchHealth, and HealthGrades. Her appointment is expected to positively impact Tactile Medical's strategic growth, market expansion in therapies for chronic conditions, and shareholder value, reinforcing the company's commitment to innovation and leadership.
Andrea A. Pearson elected to Tactile Systems Technology board, joins two committees
Andrea A. Pearson has been elected to the board of Tactile Systems Technology, effective March 9, 2026. She has also been appointed to the Compliance and Reimbursement Committee and the Nominating and Corporate Governance Committee. Pearson has a background in strategic advisory and marketing leadership roles in the healthcare sector.
Tax-cover stock sale by Tactile Systems (TCMD) CFO disclosed
Tactile Systems Technology Inc.'s CFO, Elaine M. Birkemeyer, sold 7,701 shares of common stock on February 24, 2026, to cover taxes related to stock unit settlements. The sale occurred at a weighted average price of $28.9417 per share, with individual trades ranging from $28.50 to $29.45. Following this transaction, Birkemeyer directly holds 134,819 shares of TCMD.
Tactile Systems (TCMD) CEO sells 10,993 shares to cover tax bill
Tactile Systems Technology's CEO, Sheri Louise Dodd, sold 10,993 shares of common stock on February 24, 2026, at a weighted average price of $28.9406 per share. This sale was conducted to cover tax obligations arising from the settlement of stock units. Following this transaction, Dodd directly owns 243,885 shares of the company's common stock.
Tactile Systems (TCMD) SVP sells 6,246 shares to cover taxes
Kristie Burns, Senior Vice President of Marketing & Clinical Affairs at Tactile Systems Technology Inc. (TCMD), sold 6,246 shares of common stock at a weighted average price of $28.9408 per share on February 24, 2026. This transaction was conducted to cover tax obligations associated with the settlement of stock units. Following the sale, Burns directly owns 82,581 shares of TCMD common stock.
Kristie Burns Sells 6,246 Shares of Tactile Systems Technology (NASDAQ:TCMD) Stock
Kristie Burns, VP of Tactile Systems Technology (NASDAQ:TCMD), sold 6,246 shares of the company's stock on February 24th, 2026, for a total value of $180,759.24. This transaction decreased her direct ownership by 7.03% to 82,581 shares. The company recently reported strong Q4 earnings, beating analyst estimates, and currently holds a "Moderate Buy" consensus rating from analysts with a target price of $37.40.
Tactile Systems Technology (NASDAQ:TCMD) CFO Sells $222,866.94 in Stock
Tactile Systems Technology (NASDAQ:TCMD) CFO Elaine Birkemeyer sold 7,701 shares of the company's stock, totaling $222,866.94, representing a 5.40% decrease in her holdings. This transaction followed the company reporting quarterly earnings that exceeded expectations, with EPS of $0.46 against an estimated $0.44 and revenue of $103.59 million compared to $93.80 million. The stock currently holds a "Moderate Buy" consensus rating from analysts, with a target price of $37.40.
Wall Street Analysts Think Tactile Systems Technology (TCMD) Could Surge 28.34%: Read This Before Placing a Bet
Wall Street analysts project a potential 28.3% upside for Tactile Systems Technology (TCMD) based on a mean price target of $38, despite a closing price of $29.61. While analysts' price targets can be misleading, the strong consensus in EPS estimate revisions, leading to a Zacks Rank #2 (Buy), suggests a legitimate reason for optimism regarding the stock's near-term potential. Investors are advised to consider price targets with skepticism but note that positive earnings estimate trends are often correlated with stock price movements.
Tactile Systems Technology, Inc. (NASDAQ:TCMD) Given Consensus Recommendation of "Moderate Buy" by Analysts
Tactile Systems Technology, Inc. (TCMD) has received a "Moderate Buy" consensus recommendation from analysts, with an average 12-month price target of $37.40. This follows several firms raising their price targets and an upgrade to "strong-buy" by Wall Street Zen. The company recently reported strong earnings, beating EPS and revenue expectations, and institutional ownership remains high, though a VP recently sold shares.
Tactile Systems (TCMD) CEO sells 15,240 shares, gains PSU awards
Tactile Systems Technology CEO Sheri Louise Dodd acquired 47,967 common shares through performance stock units (PSUs) tied to 2025 results and sold 15,240 common shares to cover taxes associated with these stock units. The sales occurred in open-market transactions with weighted average prices ranging from $28.2826 to $28.6891 per share. After these transactions, Dodd directly holds 254,878 common shares.
Tactile Systems Technology (TCMD) Price Target Increased by 27.73% to 38.76
The average one-year price target for Tactile Systems Technology (NasdaqGM:TCMD) has been increased by 27.73% to $38.76 per share, up from $30.34. This new target represents a 35.29% increase from the last reported closing price of $28.65. Institutional ownership in TCMD has seen some shifts, with notable changes in holdings from firms like Cadian Capital Management, Acadian Asset Management, and Paradigm Capital Management.
Tactile Systems Technology (TCMD) Reports 12% Revenue Growth to $329.5M for 2025
Tactile Systems Technology Inc. (TCMD) announced a 12% increase in total revenue for 2025, reaching $329.5 million, and completed the year with $83.4 million in cash. The company acquired Lymphotec to integrate fluid-monitoring technology and enhance patient surveillance for lymphedema. Despite a positive outlook driven by past investments and Medicare changes, Tactile projects 8% to 11% revenue growth for 2026, anticipating a short-term headwind from new Medicare prior authorization requirements for pneumatic compression devices.
Tactile Systems Technology (NASDAQ:TCMD) VP Sells $125,623.70 in Stock
Tactile Systems Technology (NASDAQ:TCMD) VP Kristie Burns sold 4,439 shares of company stock for a total of $125,623.70, reducing her stake by 4.76%. This insider sale follows the company reporting better-than-expected quarterly earnings and revenue. Analysts have a "Moderate Buy" consensus rating with an average target price of $37.40 for TCMD.
Elaine Birkemeyer Sells 5,518 Shares of Tactile Systems Technology (NASDAQ:TCMD) Stock
Tactile Systems Technology (NASDAQ:TCMD) CFO Elaine Birkemeyer sold 5,518 shares of the company's stock on February 23rd at an average price of $28.30, totaling $156,159.40. This transaction reduced her stake by 3.73%, leaving her with 142,520 shares. The sale follows strong Q4 earnings, where the company beat revenue and EPS expectations, and analysts have become more positive about the stock, with Piper Sandler raising its price target to $42.
Insider Selling: Tactile Systems Technology (NASDAQ:TCMD) CEO Sells 15,240 Shares of Stock
Tactile Systems Technology (NASDAQ:TCMD) CEO Sheri Louise Dodd sold 15,240 shares of the company's stock for $431,292, reducing her stake by 5.64%. The sale occurred after the company exceeded quarterly earnings and revenue estimates. Analysts currently rate TCMD as a "Moderate Buy" with a consensus price target of $37.40.
[144] TACTILE SYSTEMS TECHNOLOGY INC SEC Filing
This article details a Form 144 SEC filing by Tactile Systems Technology Inc. (TCMD) dated February 23, 2026. The filing indicates a proposed sale of 15,240 shares of common stock with an aggregate market value of $431,246.28, acquired through restricted stock vesting. The securities are to be sold through Fidelity Brokerage Services LLC on NASDAQ.
Tactile Systems Technology (NASDAQ:TCMD) Trading Down 9.6% - Time to Sell?
Tactile Systems Technology (NASDAQ:TCMD) saw its stock price decline by 9.6% on Thursday, with trading volume significantly below its daily average. Despite beating earnings estimates and analysts maintaining a "Moderate Buy" consensus with an average target of $37.40, a notable insider share sale occurred. The company, a medical device firm specializing in compression therapy systems, has a market capitalization of $674.44 million and is 83.43% institutionally owned.
Tactile Systems Technology (TCMD) Is Up 19.7% After Strong Q4, 2026 Outlook And LymphaTech Deal
Tactile Systems Technology (TCMD) reported strong Q4 2025 financial results with increased revenue and net income, alongside issuing optimistic 2026 revenue guidance of US$357 million to US$365 million. The company also announced the acquisition of LymphaTech, a digital lymphedema platform, integrating digital capabilities with its growth strategy. This news led to a significant 19.7% rise in TCMD's stock, though investors are cautioned about potential Medicare policy changes affecting future performance.
Tactile Systems Technology (TCMD) Recently Broke Out Above the 20-Day Moving Average
Tactile Systems Technology (TCMD) has recently broken above its 20-day moving average, signaling a short-term bullish trend. The stock has rallied 8.3% over the past four weeks and holds a Zacks Rank #2 (Buy), supported by positive earnings estimate revisions. This technical breakout and strong fundamentals suggest potential for further gains.
Tactile Systems Acquires LymphaTech To Expand Lymphedema Solutions Portfolio
Tactile Medical has acquired LymphaTech Inc. for $6.8 million, aiming to broaden its lymphedema solutions portfolio with digital and connected care technologies. LymphaTech specializes in a 3D full-body measurement and monitoring platform for lymphedema, offering precise measurements and tracking capabilities. This acquisition helps Tactile Medical move from being a product-based company to a comprehensive solutions leader for lymphatic dysfunction.
Tactile Systems Technology Shares Surge after Record-Breaking Q4 Earnings
Tactile Systems Technology (NASDAQ: TCMD) shares surged by over 18% following a record-breaking Q4 earnings report, surpassing revenue and EPS forecasts. The company achieved strong financial results with a 75% gross margin, $8.21M net income, and strategically acquired LymphaTech for $6.8M to enhance its digital health portfolio. This performance and strategic expansion have fueled investor confidence, indicating promising future growth and market prominence.
Tactile Medical Acquires LymphaTech, Expanding Breadth and Depth of its Lymphedema Solutions Portfolio
Tactile Medical has acquired LymphaTech Inc. for an upfront cash payment of $6.8 million, with additional payments contingent on future milestones. This acquisition aims to enhance Tactile Medical's lymphedema portfolio by integrating LymphaTech's 3D measurement and monitoring platform, which improves disease identification, accelerates therapy adoption, and supports next-generation lymphatic therapies. The integration is expected to strengthen Tactile Medical's market leadership and expand its research and development capabilities in treating lymphatic dysfunction.
Tactile Systems Technology, Inc. (NASDAQ:TCMD) Q4 2025 Earnings Call Transcript
Tactile Medical reported strong Q4 and full-year 2025 financial results, with total revenue up 12% year-over-year to $329.5 million and adjusted EBITDA increasing 21% to $44.8 million. The company also announced the acquisition of LymphaTech, expanding its lymphedema solutions with digital 3D scanning technology. For 2026, Tactile Medical anticipates total revenue between $357 million and $365 million, representing 8% to 11% growth, while also addressing potential short-term impacts from new Medicare prior authorization requirements and continuing strategic investments in technology and sales force optimization.
Tactile Systems Technology Analysts Raise Their Forecasts After Better-Than-Expected Q4 Earnings
Tactile Systems Technology reported better-than-expected Q4 earnings and sales, surpassing analyst consensus. The company also provided a strong fiscal 2026 outlook and announced the acquisition of LymphaTech. Following these positive results, several analysts, including those from BTIG and Piper Sandler, raised their price targets for TCMD stock.
Tactile Systems Stock Smashes 52-Week High After Strong Quarter
Tactile Systems Technology (NASDAQ:TCMD) shares hit a 52-week high after reporting strong fourth-quarter earnings that surpassed analyst expectations and announcing the acquisition of LymphaTech. This strategic acquisition, aimed at enhancing lymphedema solutions, alongside robust financial performance and optimistic 2026 forecasts, has driven significant positive momentum for the stock. Analysts maintain a "Buy" rating with increased price targets, reflecting confidence in the company's growth trajectory and market position in the medical technology sector.
Tactile Systems Technology Inc (TCMD) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Acquisitions Amid Regulatory Challenges
Tactile Systems Technology Inc (TCMD) reported a 12% increase in total revenue for 2025, reaching $329.5 million, with expanded gross margins and a 21% increase in adjusted EBITDA. The company also successfully repaid debt, repurchased stock, and acquired Lymphotec to enhance its lymphedema assessment capabilities. However, these positive developments are tempered by a new Medicare prior authorization requirement that may temporarily impact the lymphedema market and led to increased operating expenses.
Tactile Systems Technology, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
Tactile Systems Technology, Inc. reported robust financial results for Q4 and full-year 2025, with total revenue increasing 21% and 12% year-over-year, respectively. The company achieved significant net income and Adjusted EBITDA growth, repaid its term loan, and repurchased shares. Tactile Medical projects continued growth in 2026, with an expected total revenue range of $357 million to $365 million.
Tactile Systems Technology Inc (TCMD) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Acquisitions Amid Regulatory Challenges
Tactile Systems Technology Inc (TCMD) reported a 12% increase in revenue and 21% rise in adjusted EBITDA for 2025, driven by strategic investments and the acquisition of Lymphotec. The company successfully repaid debt and repurchased stock, ending the year with strong cash flow. Despite positive performance and strategic growth initiatives, the company anticipates a temporary slowdown in the lymphedema market due to new Medicare prior authorization requirements, which is reflected in their 2026 guidance.
Tactile Systems Technology Q4 Earnings Call Highlights
Tactile Systems Technology (NASDAQ: TCMD) reported strong double-digit revenue growth and improved profitability for Q4 and the full year 2025, driven by its lymphedema franchise and a significant increase in airway clearance revenue. The company also announced the acquisition of LymphaTech to enhance its integrated lymphedema solutions. Despite positive momentum, the 2026 outlook includes potential short-term disruption from a new Medicare prior authorization requirement for pneumatic compression devices, though management expects to mitigate the impact through prior investments and existing experience with similar authorization processes.
Tactile Systems Posts Strong Q4 Results and 2026 Outlook
Tactile Medical reported strong Q4 2025 results, with a 21% year-over-year revenue increase to $103.6 million and improved profitability. For the full year 2025, revenue grew 12% to $329.5 million, with net income reaching $19.1 million and adjusted EBITDA climbing to $44.8 million. The company strengthened its financial position, became debt-free, repurchased shares, and acquired LymphaTech, while also providing a positive 2026 outlook.
Tactile Systems Technology: Q4 Earnings Snapshot
Tactile Systems Technology Inc. (TCMD) reported strong fourth-quarter results, with earnings of $10.6 million and net income of 46 cents per share, surpassing Wall Street's expectations. The medical device company also exceeded revenue forecasts, posting $103.6 million for the quarter. For the full year, Tactile Systems Technology achieved a profit of $19.1 million on revenue of $329.5 million and projects future annual revenue between $357 million and $365 million.
Tactile Medical Acquires LymphaTech, Expanding Breadth and Depth of its Lymphedema Solutions Portfolio
Tactile Medical has acquired LymphaTech Inc. for $6.8 million upfront, plus potential future considerations. This acquisition expands Tactile Medical's lymphedema solutions portfolio by integrating LymphaTech's 3D measurement and monitoring platform, enhancing disease identification and treatment. The deal aims to strengthen Tactile Medical's market leadership and advance its research in lymphatic dysfunction.
Med-tech firm Tactile Medical wipes out $26.3M debt, lifts 2025 sales 12%
Tactile Medical reported strong Q4 and full-year 2025 financial results, with revenues increasing by 21% and 12% respectively. The company fully repaid its $26.3 million term loan and repurchased $26.5 million of stock, ending the year with $83.4 million in cash. Tactile Medical also provided optimistic 2026 guidance, projecting revenue growth of 8% to 11% and increased Adjusted EBITDA.
